Dual Single‐Atom Engineered NADH Oxidase‐Mimic Boosts In Situ NAD + Biotransformation for Targeted Myocardial Ischemia/Reperfusion Protection
Advanced Materials · 2026
DOI: 10.1002/adma.202519122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2026. Verfasst von Jingtao Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiaotong University School of Medicine, China. Hauptthemen laut MEDLINE: NAD, Myocardial Reperfusion Injury, NADH, NADPH Oxidoreductases, Multienzyme Complexes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: Institutional Animal Care and Use Committee at the Shanghai Chest Hospital, National Natural Science Foundation of China, China National Postdoctoral Program for Innovative Talents.
Abstract (Originalsprache)
Myocardial ischemia/reperfusion (I/R) injury is a globally recognized pathological condition that results in life‐threatening organ dysfunction. Supplementation with nicotinamide adenine dinucleotide (NAD + ) can improve myocardial energy metabolism, alleviate inflammation, and mitigate I/R injury. However, its clinical applicability is constrained by the poor efficacy and delivery limitations of current NAD + supplementation strategies. Here, we design a dual single‐atom nanozyme with nicotinamide adenine dinucleotide (NADH) oxidase‐mimicking activity for in situ NAD + biotransformation and I/R injury treatment. Upon M2 macrophage membrane coating, the nanozyme selectively targets ischemic myocardium, facilitating in situ NAD + biotransformation by eliminating excess NADH, while concurrently scavenging reactive oxygen species, restoring mitochondrial bioenergetics, attenuating inflammation, and inhibiting apoptosis. Mechanistic investigations demonstrate that the nanozyme activates the NAD + ‐SIRT1 axis, enhancing ATP biosynthesis and oxidative phosphorylation, while suppressing TNF signaling and NF‐κB pathways. Collectively, the engineered NOX‐like nanozyme offers a novel therapeutic strategy for myocardial I/R injury by modulating both mitochondrial bioenergetics and oxidative stress defense pathways through restoring NAD + /NADH homeostasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiaotong University School of Medicine, China.
- Department of Ultrasound, The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ultrasound Molecular Imaging, Chongqing, P. R. China.
- Ultrasound Department of the Second Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ultrasound Molecular Imaging, Chongqing, P. R. China.
- Materdicine Lab, School of Life Sciences, Shanghai University, Shanghai, P. R. China.
- Department of Radiology, Shanghai Institute of Thoracic Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China.
ORCID-Profile: Jingtao Liu, Yu Chen
Förderung
- Institutional Animal Care and Use Committee at the Shanghai Chest Hospital
- National Natural Science Foundation of China
- China National Postdoctoral Program for Innovative Talents
Zitieren
APA
Liu, J., Guo, X., Wang, N., Zhang, X., Wang, X., Li, G., Hou, X., Yu, L., Chen, Y., & Li, R. (2026). Dual Single‐Atom Engineered NADH Oxidase‐Mimic Boosts In Situ NAD + Biotransformation for Targeted Myocardial Ischemia/Reperfusion Protection. Advanced Materials. https://doi.org/10.1002/adma.202519122
Vancouver
Liu J, Guo X, Wang N, Zhang X, Wang X, Li G, et al. Dual Single‐Atom Engineered NADH Oxidase‐Mimic Boosts In Situ NAD + Biotransformation for Targeted Myocardial Ischemia/Reperfusion Protection. Advanced Materials. 2026. doi:10.1002/adma.202519122
BibTeX
@article{Liu2026,
author = {Liu, Jingtao and Guo, Xun and Wang, Nan and Zhang, Xingyu and Wang, Xiaoting and Li, Guangru and Hou, Xumin and Yu, Luodan and Chen, Yu and Li, Ruogu},
title = {Dual Single‐Atom Engineered NADH Oxidase‐Mimic Boosts In Situ NAD + Biotransformation for Targeted Myocardial Ischemia/Reperfusion Protection},
journal = {Advanced Materials},
year = {2026},
doi = {10.1002/adma.202519122}
}
EUVIMED